ABEONA THERAPEUTICS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
ABEONA THERAPEUTICS INC. (ABEO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 7.35 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 6.15K shares, a 19738.71% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 1.20K shares, a 193.87% increase year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 129.00 shares, a 92.50% decline year-over-year.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 568.00 shares, a 76.47% decline from fiscal 2024.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 2.41K shares, a 96.09% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 61.77K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 6.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 7.35K shares 10-Q · filed 2026-08-13 | 7.35K shares derived: sum of 3 quarters · filed 2026-08-13 | 7.48K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 1.20K shares 10-Q · filed 2026-05-13 | 1.20K shares derived: sum of 2 quarters · filed 2026-05-13 | 1.33K shares derived: sum of 3 quarters · filed 2026-05-13 | 1.36K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 129.00 shares derived: sum of 2 quarters · filed 2026-03-17 | 160.00 shares derived: sum of 3 quarters · filed 2026-03-17 | 568.00 shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 129.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 160.00 shares derived: sum of 2 quarters · filed 2025-11-12 | 568.00 shares 10-Q · filed 2025-11-12 | 1.12K shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-06-30 | 31.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 439.00 shares 10-Q · filed 2025-08-14 | 990.00 shares derived: sum of 3 quarters · filed 2026-03-17 | 2.71K shares derived: sum of 4 quarters · filed 2026-03-17 |
| 2025-03-31 | 408.00 shares 10-Q · filed 2025-05-15 | 959.00 shares derived: sum of 2 quarters · filed 2026-03-17 | 2.68K shares derived: sum of 3 quarters · filed 2026-03-17 | |
| 2024-12-31 | 551.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 2.27K shares derived: sum of 2 quarters · filed 2026-03-17 | 2.41K shares 10-K · filed 2026-03-17 | |
| 2024-09-30 | 1.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 1.86K shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 142.00 shares 10-Q · filed 2024-08-12 | |||
| 2023-12-31 | 61.77K shares 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |